Micron Biomedical, a US-based life science company, announced on Tuesday that it has named global public health pioneer Dr Seth Berkley as scientific advisor to the CEO.
In the new role, Dr Berkley is to guide the firm's strategic manufacturing and supply chain efforts, and the go-to-market strategy including quality, distribution and pricing.
Dr Berkley is an infectious disease epidemiologist and has expertise in global health. He has worked as CEO of Gavi. He also co-founded COVAX and International AIDS Vaccine Initiative. He has served at the Special Pathogens Branch of the US Centers for Disease Control and Prevention (CDC), the Massachusetts Department of Public Health, the Ministry of Health of Uganda and the Rockefeller Foundation.
Steven Damon, Micron Biomedical CEO, said: "Vaccines are the most effective weapons we have against disease and no one has been more effective than Dr. Seth Berkley in leading the world's most successful distribution of life-saving vaccines. As Micron pivots to mass manufacturing and expanded vaccine and therapeutic indications, Dr. Berkley's expertise will bring game-changing perspectives that will allow us to even further accelerate efforts to make pharmaceuticals more accessible, more affordable and more convenient through our microarray technology."
Benuvia Operations signs licensing deal with Avernus Pharma
Benuvia Operations signs licensing and supply agreements with Medra Brasil Medicamentos
Castle Biosciences to present data on Melanoma tests at ASDP Annual Meeting
Alchemy partners with PatchRx to improve HIV medication adherence
Gilead expands global access to lenacapavir for HIV prevention
Alume Biosciences names new chief commercial officer
genedrive plc secures initial UK order for Genedrive CYP2C19-ID Kit
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Oxford BioDynamics announces opening of clinical testing facility in UK for prostate screening test
Micron Biomedical names new scientific advisor to CEO
China accepts GSK's Shingrix application for at-risk adults
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Allurion's Gastric Balloon introduced at Somerset NHS Foundation Trust for pre-surgical weight loss